The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
Two years ago, GLP-1 prescriptions cost over $1,000 monthly for uninsured patients. Now, Wegovy's pill starts at $149, flipping Big Pharma's playbook amid fierce price wars. As Novo Nordisk forecasts sales drops and Eli Lilly surges, discover how consumer demand is reshaping obesity treatments.
Weight-loss drugs like Wegovy's new pill are making a splash with multimillion-dollar Super Bowl ads featuring Kenan Thompson, DJ Khaled, and Serena Williams. As Novo Nordisk and Eli Lilly battle for market share, affordable oral GLP-1 options starting at $49 signal a new era in obesity care. See how these celebrity spots aim to reach 130 million viewers.
A senior South African Police Service official admitted under oath to asking her boyfriend's company for Ozempic amid pharmacy shortages. Brigadier Rachel Matjeng's testimony at the Madlanga Commission highlights the drug's high demand for type 2 diabetes and off-label weight loss use. The case raises questions about procurement ethics in a corruption inquiry.
Tennis icon Serena Williams has shared her inspiring weight loss story, dropping 34 pounds with GLP-1 drugs after struggling post-retirement and motherhood. Facing unknown heart disease risks, she credits the medication with transforming her health. Inside her journey and how GLP-1 works for real results.
A Liverpool mum shed 7st on Mounjaro in under a year, transforming her life—but a freezing side effect dubbed 'MJ Freeze' has spiked her energy bills by £70 a month. Emilly Murray now layers up at home with heated blankets and gloves just to stay warm. Despite the chill, she says it's worth every penny for silencing food noise and boosting her health.
Hims & Hers Health's bold launch of a $49-per-month copycat GLP-1 pill to rival Wegovy's $149 price tag backfired spectacularly. FDA Commissioner Marty Makary vowed 'swift action' against such unapproved drugs, sending HIMS shares down 7.5% in premarket trading. This regulatory showdown highlights growing tensions in the GLP-1 market dominated by Novo Nordisk and Eli Lilly.
GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have helped 1 in 8 U.S. adults lose 15-20% body weight. But after hitting your goal, what now? Dr. Amy J. Sheer shares proven steps for maintenance, plateaus, and long-term success.
Eli Lilly posted blockbuster Q4 2025 results with $19.29B revenue, yet shares near $1,020 face selling pressure from compounded semaglutide competition and government pricing initiatives. Hims & Hers' $49 pill undercuts Zepbound's $299 intro dose, signaling shifts in the GLP-1 market. Investors eye Orforglipron's FDA decision amid pipeline cuts.
Hims & Hers launched a $49-a-month compounded version of Novo Nordisk's Wegovy, promising affordable GLP-1 weight-loss treatment amid shortages. Yet, despite an initial 14% stock surge, shares closed down 4% as FDA scrutiny loomed. This move highlights tensions in the booming obesity drug market and accessibility challenges for patients.
